Active Substance: Ethosuximide.
Overview
Welcome to Dwaey, specifically on ZARONTIN 250mg page.
This medicine contains an important and useful components, as it consists of
Ethosuximideis available in the market in concentration
Ethosuximide
Hepatic or renal impairment, porphyria. Complete blood cell count, liver function tests, and urinalysis should be performed periodically. May increase the risk of grand mal seizures when used alone in mixed types of epilepsy. Avoid sudden withdrawal. May impair ability to drive or operate machinery. Lactation: enters breast milk; use with caution (AAP Committee states "compatible with nursing")
Absence seizures
Hypersensitivity. Pregnancy and lactation.
Common Dizziness,Headache,Somnolence,Anorexia,Diarrhea,GI upset,Nausea,Vomiting Less Common Ataxia, confusion, drowsiness, sleep disturbance,Gum hypertrophy, hiccoughs, swelling of tongue,Blood dyscrasias including aplastic anemia,Allergic reaction,Urticaria,Pruritic erythematous rashes,Blurred vision, myopia Rare Psychosis,Seizure,Suicidal thoughts and behavior,Stevens-Johnson syndrome,Systemic lupus erythematosus,Hirsutism
3
Ethosuximide is used mainly in the management of absence (petite mal) seizures. It is usually ineffective in the management of partial seizures with complex symptomatology or tonic-clonic seizures.
Isoniazid may increase the serum concentration of ethosuximide, leading to toxicity. Antipsychotics, antidepressants, MAOIs, and mefloquine may antagonise anticonvulsant effects of ethosuximide. Plasma conc of ethosuximide may be reduced by carbamazepine, phenobarbital, phenytoin, and primidone; and affected by valproate. Chloroquine or hydroxychloroquine may increase risk of convulsions. Isoniazid.
Information not available